Xi K X, Song S Y, Luo Z K, Sun Z G, Feng L, Zhang H Z
Department of Colorectal Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China.
State Key Laboratory of Molecular Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China.
Zhonghua Yi Xue Za Zhi. 2022 May 24;102(19):1423-1429. doi: 10.3760/cma.j.cn112137-20220214-00297.
To evaluate the impact of number-indexes of lymph nodes for prognostic stratification in stage N1c colorectal cancer (CRC) patients. The clinicopathologic data of CRC patients with stage pTxN1cM0 who initially underwent radical surgery in Cancer Hospital, Chinese Academy of Medical Sciences and the Surveillance, Epidemiology and End Results (SEER) database from January 2010 to December 2015 were retrospectively analyzed. A total of 1 165 patients with stage N1c were included in this study. Among them, 85 patients (including 54 males and 31 females) were from Cancer Hospital, Chinese Academy of Medical Sciences and their median age was 58 (range: 32-80) years; 1 080 patients (including 566 males and 514 females) were from the SEER database and their median age was 66 (range: 24-98) years. The prognostic significance of total number of lymph node (TLN), number of negative lymph node (NLN), and log odds of positive lymph nodes (LODDS) in stage N1c CRC patients were explored. The optimal cut-off value of TLN or NLN was 13, and the optimal cut-off value of LODDS was -1.43. Among the 85 patients of Cancer Hospital, Chinese Academy of Medical Sciences, the 5-year overall survival (OS) rates of stage N1c1 (TLN or NLN≥13, 69 cases) and group LODDS1 patients (LODDS≤-1.43, 69 cases) were both 80.9%, which higher than that of stage N1c2 (TLN or NLN<13, 16 cases) and group LODDS2 (LODDS>-1.43, 16 cases) patients (both 53.3%, =0.002); In the SEER cohort, the 5-year OS rates of stage N1c1 (837 cases) and group LODDS1 patients (LODDS≤-1.43, 837 cases) were both 64.7%, which higher than that of stage N1c2 (243 cases) and group LODDS2 (LODDS>-1.43, 243 cases) patients (both 52.2%, <0.001). Both in the NCC cohort and SEER cohort, the results of Cox multivariate analysis all demonstrated that TLN or NLN<13 was the risk factor of OS of CRC patients with stage N1c (=3.794, 95%: 1.539-9.349, =0.004; and =1.588, 95%:1.232-2.048, <0.001; respectively); LODDS≤-1.43 was the independent protective factor of OS of stage N1c CRC patients (=0.264, 95%: 0.107-0.650; and =0.630, 95%: 0.488-0.812; respectively). TLN or NLN and LODDS were all independent prognostic factors of CRC patients with stage N1c. The clinicians could use TLN or NLN and LODDS for prognostic stratification and make the different adjuvant therapeutic schemes for CRC patients with stage N1c.
评估淋巴结数量指标对N1c期结直肠癌(CRC)患者预后分层的影响。回顾性分析了2010年1月至2015年12月在中国医学科学院肿瘤医院初行根治性手术的pTxN1cM0期CRC患者的临床病理资料以及监测、流行病学和最终结果(SEER)数据库。本研究共纳入1165例N1c期患者。其中,85例(包括54例男性和31例女性)来自中国医学科学院肿瘤医院,他们的中位年龄为58岁(范围:32 - 80岁);1080例(包括566例男性和514例女性)来自SEER数据库,他们的中位年龄为66岁(范围:24 - 98岁)。探讨了N1c期CRC患者的淋巴结总数(TLN)、阴性淋巴结数(NLN)和阳性淋巴结对数比(LODDS)的预后意义。TLN或NLN的最佳截断值为13,LODDS的最佳截断值为 -1.43。在中国医学科学院肿瘤医院的85例患者中,N1c1期(TLN或NLN≥13,69例)和LODDS1组患者(LODDS≤ -1.43,69例)的5年总生存率(OS)均为80.9%,高于N1c2期(TLN或NLN<13,16例)和LODDS2组患者(LODDS> -1.43,16例)(均为53.3%,P = 0.002);在SEER队列中,N1c1期(837例)和LODDS1组患者(LODDS≤ -1.43,837例)的5年OS率均为64.7%,高于N1c2期(243例)和LODDS2组患者(LODDS> -1.43,243例)(均为52.2%,P<0.001)。在NCC队列和SEER队列中,Cox多因素分析结果均表明,TLN或NLN<13是N1c期CRC患者OS的危险因素(P = 3.794,95%CI:1.539 - 9.349,P = 0.004;和P = 1.588,95%CI:1.232 - 2.048,P<0.001;分别);LODDS≤ -1.43是N1c期CRC患者OS的独立保护因素(P = 0.264,95%CI:0.107 - 0.650;和P = 0.630,95%CI:0.488 - 0.812;分别)。TLN或NLN以及LODDS均为N1c期CRC患者的独立预后因素。临床医生可使用TLN或NLN以及LODDS进行预后分层,并为N1c期CRC患者制定不同的辅助治疗方案。